Celcuity

CELC · NASDAQ

$60.00+$2.88 (+5.04%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $57.12

CELC analyst rating

BuyConsensus of 11 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy11
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $156.47 (+160.8% upside)

Low: $111.10
Now: $60.00
High: $185.85

Upgrades and downgrades

The latest rating actions, newest first

CELC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Sep 30, 2026	Maintains	Buy	$140.00 → $134.00	38%
JP Morgan	Sep 17, 2026	Initiates	Overweight	$157.00	48%
Guggenheim	Aug 17, 2026	Maintains	Buy	$165.00 → $175.00	46%
Citizens	Aug 17, 2026	Maintains	Market Outperform	$177.00	14%
HC Wainwright & Co.	Aug 14, 2026	Maintains	Buy	$155.00	43%
Stifel	Aug 14, 2026	Maintains	Buy	$175.00 → $150.00	46%
Needham	Aug 14, 2026	Maintains	Buy	$157.00 → $140.00	38%
Citizens	Jul 15, 2026	Maintains	Market Outperform	$160.00 → $177.00	14%
HC Wainwright & Co.	Jul 15, 2026	Maintains	Buy	$145.00 → $155.00	43%
Craig-Hallum	Jun 3, 2026	Maintains	Buy	$189.00 → $171.00	44%

The case for and against

Updated Oct 15, 2026

Bull case

Celcuity is positioned favorably because gedatolisib combines broad PI3K/mTOR pathway inhibition with differentiated pharmacokinetics, and the Phase 3 VIKTORIA-1 program has already delivered compelling efficacy in PIK3CA WT disease while the PIK3CA MT cohort is enrolled and the PIK3CA MT sNDA is planned for 3Q26. Its outlook is further strengthened by commercial readiness for REVTORPYK, including pricing of about $10,000 per vial or $30,000 per cycle, expected late 3Q26 launch timing, and a reported 2Q26 cash balance of $754 million that supports runway into >2029. The company also has multiple expansion drivers, with VIKTORIA-2 and CELC-G-201 ongoing and manufacturing, KOL engagement, and NCCN guideline potential reinforcing a larger HR+/HER2- franchise opportunity.

Bear case

Celcuity is a high-risk, development-stage biotech whose value depends heavily on gedatolisib, yet there is no guarantee the drug will prove sufficiently effective or safe in current or future clinical trials, including formCRPC and HR+/HER2- breast cancer studies. The company also faces meaningful regulatory and commercial uncertainty, because delays or failure to secure FDA and foreign approvals could impair any eventual monetization, while clinical trial collaborations with pharma can be terminated at any time. Financially, the outlook is pressured by the likelihood of additional equity financing to fund development, which would create dilution risk for existing shareholders amid intense competition from larger, better-resourced rivals.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.